Cargando…

Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood. 2020;135(21):1912–1915.

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology. Published by Elsevier Inc. 2021
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970664/ https://www.ncbi.nlm.nih.gov/pubmed/33734339 http://dx.doi.org/10.1182/blood.2021010938

Ejemplares similares

Hansen JW, Pedersen DA, Larsen LA, et al. Clonal hematopoiesis in elderly twins: concordance, discordance, and mortality. Blood. 2020;135(4):261-268.
Publicado: (2020)

Pal K, Nowak R, Billington N, et al. Megakaryocyte migration defects due to nonmuscle myosin IIA mutations underlie thrombocytopenia in MYH9-related disease. Blood. 2020;135(21):1887-1898.
Publicado: (2020)

Cartas de amor a Margarita (1912-1915) /
por: Salinas, Pedro, 1892-1951
Publicado: (1984)

Chen J-J. HRI stress signaling and HbF production. Blood. 2020;135(24):2113-2114.
Publicado: (2020)

Ibrutinib and novel BTK inhibitors in clinical development
por: Akinleye, Akintunde, et al.
Publicado: (2013)

PB1912: BTK AND PLCG2 GENE MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH RESISTANCE TO COVALENT BTK INHIBITOR
por: Likold, Ekaterina, et al.
Publicado: (2023)

Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner
por: Liu, Jia, et al.
Publicado: (2022)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

Ibrutinib directly reduces CD8+T cell exhaustion independent of BTK
por: Li, Ling, et al.
Publicado: (2023)

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
por: Nicolson, Phillip L.R., et al.
Publicado: (2018)

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL
por: Sharma, Shruti, et al.
Publicado: (2016)

Controlling Ibrutinib’s Conformations about Its Heterobiaryl Axis to Increase BTK Selectivity
por: Toenjes, Sean T., et al.
Publicado: (2023)

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
por: Shanafelt, Tait D., et al.
Publicado: (2022)

A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells
por: Natarajan, Gayathri, et al.
Publicado: (2016)

Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer
por: Zhu, Zhen, et al.
Publicado: (2020)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

Erratum to “A Case of Bing–Neel Syndrome Successfully Treated with Ibrutinib”
por: O'Neil, Daniel S., et al.
Publicado: (2018)

Erratum: Yoon, J.J., et al. Dianthus superbus Improves Glomerular Fibrosis and Renal Dysfunction in Diabetic Nephropathy Model. Nutrients 2019, 11, 553
por: Yoon, Jung Joo, et al.
Publicado: (2020)

Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer
por: Zucha, Muhammad Ary, et al.
Publicado: (2015)

Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice
por: Schutt, Steven D., et al.
Publicado: (2015)

Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis
por: Colado, Ana, et al.
Publicado: (2018)

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients
por: Treon, Steven P., et al.
Publicado: (2020)

Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies
por: Zhu, Sining, et al.
Publicado: (2021)

Ibrutinib facilitates the sensitivity of colorectal cancer cells to ferroptosis through BTK/NRF2 pathway
por: Zhu, Jin-Feng, et al.
Publicado: (2023)

Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib
por: Guo, Ailin, et al.
Publicado: (2015)

Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia
por: de Porto, Alexander P., et al.
Publicado: (2019)

Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers
por: Yang, Xuedong, et al.
Publicado: (2019)

Ibrutinib Prevents Acute Lung Injury via Multi-Targeting BTK, FLT3 and EGFR in Mice
por: Rao, Huanan, et al.
Publicado: (2022)

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
por: Chiodin, Giorgia, et al.
Publicado: (2022)

Fabrizio VA, Boelens JJ, Mauguen A, et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022;6(7):1961-1968.
Publicado: (2023)

J.J. Rousseau /
por: Faguet, Emile, 1847-1916
Publicado: (1945)

Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes
por: Zhu, Sining, et al.
Publicado: (2021)

1912 + 1
por: Sciascia, Leonardo, 1921-1989
Publicado: (1989)

The Services in 1912
Publicado: (1913)

1915 /
por: Gómez Morín, Manuel, 1897-1972
Publicado: (2002)

Electroweak production of $Z$jj and $W^{\pm}W^{\pm}$jj states at the LHC
por: Pagan Griso, S.
Publicado: (2014)

El castillo
por: Kafka, Franz, 1883-1924
Publicado: (1949)

El castillo
por: Kafka, Franz, 1883-1924
Publicado: (1949)

El castillo
por: Kafka, Franz, 1883-1924
Publicado: (1982)

Castillo interior /
por: Méndez, Roberto, 1958-
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_7vpuii2kbgj3a1v46q6ld8v10b